These data suggest that the HER2-positive and HER2-negative components of each case are clonally related and that there is no highly recurrent alternative CNA in the HER2-negative components of HER2 heterogeneous breast cancers that compensates for the lack of HER2 gene amplification. This evidence concerns the gene ERBB2 and breast carcinoma.